AGTR1 and pulmonary arterial hypertension: These results demonstrate that antagonizing both β-arrestin and G protein–dependent AT1R signaling is beneficial in PAH, but the selective inhibition of G protein–dependent signaling with a β-arrestin–biased agonist (TRV023) did not improve hemodynamics or outcomes in PAH.